Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Tempus AI | Teradyne | GitLab | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." | narrow Real but bounded: the FY2025 10-K reports gross profit at 58.2% of total revenues, a level it records as a decrease - 'Gross profit as a percent of total revenues decreased by 0.3 points, primarily due to product mix' from 58.5% in 2024 - while a shared IG-XL test-program environment spans the FLEX and J750 families. Against that, the filing's own risk-factor heading is 'We are subject to intense competition' and it concedes that 'Some of our competitors have introduced or announced new products with certain performance characteristics that may be considered equal or superior to those we currently offer,' adding that it faces competition 'from emerging Asian companies and internal development at several of our customers.' | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. |
| Moat type | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. | switching costs The 10-K's Products section grounds the stickiness in test-program and capital reuse rather than in protected IP: the FLEX Test Platform runs 'The IG-XL™ software operating system which provides fast program development, including instant conversion from single to multi-site test', the J750 'shares the IG-XL software environment with the family of FLEX Test Platform systems,' and its instruments are 'coupled with a universal slot test head design that allows easy test system reconfiguration to address changing test needs.' The filing credits that versatility with making FLEX 'a widely used test solution at OSATs... allowing OSATs to leverage their capital investments.' The same 10-K expressly disclaims an IP-based moat: 'We do not believe that any single piece of intellectual property or proprietary rights is essential to our business.' | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." |
| Leadership | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. | co leader The 10-K opens by calling Teradyne 'a leading global provider of automated test equipment and robotics solutions' - a leading provider, not the leader - and its Competition section names Semiconductor Test rivals non-exhaustively: competitors 'include, among others, Advantest Corporation, SPEA S.p.A., and Cohu, Inc.' It discloses no share figure and warns that competitors' announced products 'may be considered equal or superior to those we currently offer,' which reads as shared leadership rather than a clear lead. | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. |
| Pricing power | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). | moderate Gross profit was 58.2% of total revenues in 2025 against 58.5% in 2024, and the 10-K attributes the 0.3-point decline to product mix; product gross margin fell 0.8 points to 57.3%. The risk factor 'Our operating results are likely to fluctuate significantly' lists 'competitive pressures on selling prices' among factors that 'could impact future operations,' and the same list cites the tendency of customers to 'wait until late in a quarter to commit to purchase... or the hope of obtaining more favorable pricing from a competitor seeking the business' - margin is defended, not expanded. | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." |
| Summary | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. | Teradyne sells the test step that sits between fabrication and shipment, and its hold on customers comes from platform continuity rather than patents. The FY2025 10-K describes one IG-XL software environment shared across the FLEX and J750 test families and a universal slot test head that lets a customer reconfigure a system to address changing test needs, which the filing credits with making FLEX widely used at OSATs because it lets them leverage their capital investments. The margin that continuity sits on is high but not rising: gross profit was 58.2% of revenue in 2025, which the filing records as a 0.3-point decrease from 2024 on product mix, with product margin down 0.8 points to 57.3% and service margin up 2.9 points to 62.9% - and the filing attributes that service gain to the May 2024 sale of the DIS business, not to the platform. It is a narrow moat, not a wide one: the filing names Advantest, SPEA and Cohu 'among others' in Semiconductor Test, warns of internal development at several customers, states that rival products may be 'equal or superior,' and discloses that the five largest direct customers rose to 44% of consolidated revenue in 2025 from 36% in 2024 - buyer power that caps how much of the platform advantage converts to price. | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". |
| Chain position | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. | Back-end capital equipment: its testers sit between fabrication and shipment, and the 10-K states that AI related customer demand drove the majority of revenue in the second half of 2025, with Semiconductor Test at 79% of consolidated revenue. | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. |